Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials
Cancer Treatment Reviews · 2026
DOI: 10.1016/j.ctrv.2026.103093 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2026. Verfasst von Najwaa Kirmani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dow Medical College, Karachi, Pakistan. Hauptthemen laut MEDLINE: Breast Neoplasms, Selective Estrogen Receptor Modulators. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dow Medical College, Karachi, Pakistan.
- Universidad de los Andes, Bogotá, Colombia.
- Pontificia Universidad Javeriana, Bogotá, Colombia.
- Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
- Government Medical College Kozhikode, Kerala, India.
- Grupo de Investigación en Ciencias Quirúrgicas, Departamento de Ciencias Clínicas, Universidad Tecnológica de Pereira, Pereira, Colombia; Institución Universitaria Visión de las Américas, Pereira, Colombia. Electronic a…
Zitieren
APA
Kirmani, N., De León-Fernández, N., Rodriguez-Parra, J. D., Ghanem, L., Hakkeem, B., Briceño-Morales, C., & Briceño-Morales, X. (2026). Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2026.103093
Vancouver
Kirmani N, De León-Fernández N, Rodriguez-Parra JD, Ghanem L, Hakkeem B, Briceño-Morales C, et al. Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials. Cancer Treatment Reviews. 2026. doi:10.1016/j.ctrv.2026.103093
BibTeX
@article{Kirmani2026,
author = {Kirmani, Najwaa and De León-Fernández, Nathalia and Rodriguez-Parra, Juan David and Ghanem, Laura and Hakkeem, Bezalel and Briceño-Morales, Clara and Briceño-Morales, Ximena},
title = {Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials},
journal = {Cancer Treatment Reviews},
year = {2026},
doi = {10.1016/j.ctrv.2026.103093}
}
EUVIMED